Home
About
Overview
Sharing Data
ORCID
Help
History (45)
Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention.
Virus Diseases
Venae Cavae
Back Injuries
Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent.
See All 45 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent.
Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. J Am Coll Cardiol. 2020 09 08; 76(10):1274-1275.
View in:
PubMed
subject areas
Aspirin
Diabetes Mellitus
Humans
Percutaneous Coronary Intervention
Purinergic P2Y Receptor Antagonists
authors with profiles
Usman Baber